Roche unveils completely new sequencing approach
Roche researchers have introduced a greatly improved long-read nanopore sequencing method that has the potential to erase the sequencing-by-synthesis approach of market leader Illumina.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Roche researchers have introduced a greatly improved long-read nanopore sequencing method that has the potential to erase the sequencing-by-synthesis approach of market leader Illumina.
Investment company Frazier Life Sciences has launched the virtual ADC company Callio Therapeutics Inc by licencing Hummingbird Bioscience’s TopDDRive dual payload ADC technology and co-leading a US$187m financing round with French Jeito Capital and other investors.
The European Commission has presented its long-awaited Clean Industrial Deal, which aims at replacing its Green Deal in times of geopolitical tensions, slow economic growth and technological competition with “a transformational business plan” that makes the world’s 2nd largest economic bloc future-proof, sustainable while improving global competitiveness.
Fuse Vectors has secured US$5.2m in pre-seed financing to revolutionise gene therapy manufacturing with its cell-free viral vector technology. The Danish company is aiming to make treatments more accessible and cost-effective by streamlining production.
Krakow-based oncology specialist Ryvu Therapeutics zoo today announced a strategic reorganisation that will extend Ryvu’s cash runway to H2/2026 to focus on accelerating three ongoing RVU120 clinical programmes, and early pipeline small molecule and ADC assets to key data inflection points.
With a 7.7% lead, the incoming Christian Democrat Chancellor Friedrich Merz has put the radical right-wing AfD in its place. Before forming a government in Germany, Merz emphasised that Germany wants to strengthen the EU’s self-sufficiency, although the role of biotechnology seems to be of secondary importance to him.
French targeted DNA gene therapy specialist EG427 has closed a €27m Series B financing co-led by VC investor Andera Partners and BPI France to initiate Phase I testing of a Herpes Simplex Virus 1 (nrHSV-1) vector that specifically targets type C neurons to suppress dysfunctions of the bladder in people with spinal injury.
LINDIS Biotech GmbH has selected Swiss Celonic Group to manufacture its recently EU-approved malignant ascites treatment catumaxomab for commercial supply.
German-Canadian food tech specialist The Cultivated B reports that it has identified a small molecule that can replace bovine fibroblast growth factor (bFGF) in the production of cell-based meat with a stable, scalable small molecule that results in reproducible quality of sustainably cultured meat.
The new fund supports of NaturalX, which has its first closing at €100m, supports proactive healthcare, filling a market gap as consumers take control of their own health journey.